Priority Research Papers:
Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2192 views | HTML 3057 views | ?
Abstract
Kacie A. Gardella2,*, Israel Muro1,*, Gloria Fang1, Krishnakali Sarkar2, Omayra Mendez2 and Casey W. Wright1,2
1 Division of Pharmacology and Toxicology, and the Center for Molecular and Cellular Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA
2 Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX, USA
* These authors have contributed equally to this work
Correspondence to:
Casey W. Wright, email:
Keywords: alternative splicing, ARNT, RelB, p53, lymphoid malignancies
Received: September 22, 2015 Accepted: January 22, 2016 Published: February 20, 2016
Abstract
The aryl hydrocarbon receptor nuclear translocator (ARNT) is involved in xenobiotic and hypoxic responses, and we previously showed that ARNT also regulates nuclear factor-κB (NF-κB) signaling by altering the DNA binding activity of the RelB subunit. However, our initial study of ARNT-mediated RelB modulation was based on simultaneous suppression of the two ARNT isoforms, isoform 1 and 3, and precluded the examination of their individual functions. We find here that while normal lymphocytes harbor equal levels of isoform 1 and 3, lymphoid malignancies exhibit a shift to higher levels of ARNT isoform 1. These elevated levels of ARNT isoform 1 are critical to the proliferation of these cancerous cells, as suppression of isoform 1 in a human multiple myeloma (MM) cell line, and an anaplastic large cell lymphoma (ALCL) cell line, triggered S-phase cell cycle arrest, spontaneous apoptosis, and sensitized cells to doxorubicin treatment. Furthermore, co-suppression of RelB or p53 with ARNT isoform 1 prevented cell cycle arrest and blocked doxorubicin induced apoptosis. Together our findings reveal that certain blood cancers rely on ARNT isoform 1 to potentiate proliferation by antagonizing RelB and p53-dependent cell cycle arrest and apoptosis. Significantly, our results identify ARNT isoform 1 as a potential target for anticancer therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7539